ETFs Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.